Method for predicting the need for dose reductions in chemotherapy for patients with breast cancer: a potential decision aid for the use of myeloid growth factors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 28, 2002
app pub date -
Jun 25, 2001
filing date -
Oct 12, 1999
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention provides provided a method and instrument for predicting the probability of a patient requiring a significant dose reduction in adjuvant chemotherapy for breast cancer and/or predicting whether early treatment with a myeloid growth factor is warranted, by determining the patient's dose-adjusted nadir absolute neutrophil count (ANC) in the first cycle of the chemotherapy schedule, further determining the patient's dose-adjusted percent change in platelet count from day one to the dose-adjusted nadir platelet count in the first cycle of the chemotherapy schedule, and then calculating the probability that the patient will receive a suboptimal chemotherapy dose using the dose-adjusted nadir ANC and dose-adjusted percent change in platelet count.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully